
    <!DOCTYPE html>
    <html lang="ja">
    <head>
        <meta charset="UTF-8">
        <title>Nightly Research Report</title>
        <style>
            body { font-family: sans-serif; line-height: 1.6; max-width: 1000px; margin: auto; padding: 20px; background: #f4f4f4; }
            .card { background: white; padding: 20px; margin-bottom: 20px; border-radius: 8px; box-shadow: 0 2px 5px rgba(0,0,0,0.1); }
            h1 { color: #333; border-bottom: 2px solid #333; }
            h2 { color: #0056b3; margin-top: 0; }
            .tag { display: inline-block; background: #e0e0e0; border-radius: 4px; padding: 2px 8px; font-size: 0.8em; margin-right: 5px; }
            .meta { font-size: 0.9em; color: #666; margin-bottom: 10px; }
            .takeaway { font-weight: bold; color: #d9534f; margin-top: 10px; }
            .relevance { background: #e7f3ff; padding: 10px; border-left: 4px solid #0056b3; margin-top: 10px; }
        </style>
    </head>
    <body>
        <h1>Nightly Research Report (Builder Analysed)</h1>
        <p>Generated: 2026-02-24</p>
    
        <div class="card">
            <h2>Uncovering the molecular and immunological defects in multicentric carpotarsal osteolysis syndrome: identification of relevant biomarkers</h2>
            <div class="meta">Front Immunol (2026) | Category: MAFB | Priority: High</div>
            <div>
                <span class="tag">MCTO</span> <span class="tag">bone</span> <span class="tag">kidney</span> <span class="tag">macrophage</span>
            </div>
            <div class="takeaway">Key Takeaway: Novel MAFB variant (c.187C>T) affects phosphorylation (Loss Thr62, Gain Ser63) reducing transactivation. NSAIDs risk identified.</div>
            <div class="relevance">My Project Relevance: Directly links MAFB mutations to macrophage subset shifts (CD16+) and kidney phenotype (FSGS). Very high relevance to MAFB project.</div>
            <p><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12605331/" target="_blank">View Paper</a> | DOI: </p>
        </div>
        
        <div class="card">
            <h2>EHBP1 suppresses liver fibrosis in metabolic dysfunction-associated steatohepatitis</h2>
            <div class="meta">Cell Metab (2025) | Category: Natto-Project | Priority: High</div>
            <div>
                <span class="tag">MASH</span> <span class="tag">liver fibrosis</span> <span class="tag">EHBP1</span> <span class="tag">sortilin</span> <span class="tag">retromer</span>
            </div>
            <div class="takeaway">Key Takeaway: EHBP1 stabilizes retromer/sortilin to promote PCSK9 secretion, reducing LDLR/TAZ-driven fibrosis.</div>
            <div class="relevance">My Project Relevance: EHBP1/PCSK9/TAZ axis provides new targets for Natto-Project interventions in MASH/fibrosis.</div>
            <p><a href="https://doi.org/10.1016/j.cmet.2025.01.020" target="_blank">View Paper</a> | DOI: 10.1016/j.cmet.2025.01.020</p>
        </div>
        
        <div class="card">
            <h2>Gut microbiota and metabolomics in metabolic dysfunction-associated fatty liver disease: interaction, mechanism, and therapeutic value</h2>
            <div class="meta">Front Cell Infect Microbiol (2025) | Category: Natto-Project | Priority: Medium</div>
            <div>
                <span class="tag">MAFLD</span> <span class="tag">MASH</span> <span class="tag">gut-liver axis</span> <span class="tag">metabolomics</span> <span class="tag">SCFA</span> <span class="tag">FXR</span>
            </div>
            <div class="takeaway">Key Takeaway: Comprehensive review of microbial drivers (SCFA, TLR4, bile acids) and AI models for diagnosis.</div>
            <div class="relevance">My Project Relevance: Provides benchmarks for our Natto-derived metabolite analysis (butyrate focus).</div>
            <p><a href="https://doi.org/10.3389/fcimb.2025.1635638" target="_blank">View Paper</a> | DOI: 10.3389/fcimb.2025.1635638</p>
        </div>
        
    </body>
    </html>
    